To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

Sumitomo Pharma

Status and phase

Completed

Phase 3

Conditions

Chronic Bronchitis

Chronic Obstructive Pulmonary Disease

Emphysema

Treatments

Drug: Salmeterol

Drug: arformoterol

Study type

Interventional

Funder types

Industry

Identifiers

NCT00064415

091-060

Details and patient eligibility

About

The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD

Full description

This was a multicenter, open-label, randomized, active controlled, parallel group chronic safety study of arformoterol 50 mcg once daily over a period of 12 months in subjects with COPD. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Enrollment

799 patients

Sex

All

Ages

35+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

INCLUSION CRITERIA: In order to qualify for participation, subjects must meet the following criteria:

Must give written informed consent prior to participation. Women of childbearing potential must also sign the Women of Childbearing Potential Addendum.
Must be willing to comply with study procedures and visit schedule
Male or female >35 years of age
Female subjects <65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization. Subjects of childbearing potential must be using an acceptable method of birth control.
Female subjects who are considered not of childbearing potential must be: (1) documented surgically sterile, OR (2) postmenopausal
Have a primary diagnosis of COPD, which may include components of chronic bronchitis and/or emphysema. Diagnosis can be made during the screening process.
Have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years)
Medical Research Council (MRC) Dyspnea Scale Score >2
Have a baseline FEV1 <65% of predicted normal value and >0.70 L documented prior to randomization
Have an FEV1/FVC ratio <70% documented prior to randomization.
Have a chest x-ray that is consistent with the diagnosis of COPD and taken <3 months prior to Visit 1. If there is no chest x-ray taken 3 months prior to Visit 1, a chest x-ray will be performed prior to Visit 2.
Be able to complete all study questionnaires and logs reliably

EXCLUSION CRITERIA: In order to qualify for participation, subjects must not meet any of the following criteria:

Currently using disallowed medications or will be unable to complete the medication washout periods
Female subject who is pregnant or lactating
Have participated in an investigational drug study within 30 days prior to Visit 1 or who is currently participating in another investigational drug study
Subject whose schedule or travel prevents the completion of all required visits
Subject who is scheduled for in-patient hospitalization, including elective surgery (in-patient or out-patient) during the trial.
Subject with life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days prior to Visit 1
Known history of asthma or any chronic respiratory disease (including a current history of sleep apnea) other than COPD (chronic bronchitis and/or emphysema).
Subject with a blood eosinophil count >5%
Subject with clinically significant cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol
History of cancer except non-melanomatous skin cancer
History of lung resection of more than one full lobe
Subject who requires continuous supplemental oxygen therapy. The use of supplemental oxygen, not to exceed 2 L/minute, at nighttime only and/or only during exercise is allowed.
Have had a change in dose or type of any medications for COPD within 14 days prior to the screening visit
Have a known sensitivity to (R,R)-formoterol, ipratropium, salmeterol or albuterol or any of the excipients contained in any of these formulations
Have clinically significant abnormalities that may interfere with the metabolism or excretion of the study drug
Have a history of substance abuse or drug abuse within 12 months of Visit 1 or with a positive urine drug screen at the screening visit
Subject with clinically significant abnormal laboratory values
Subject with clinically significant abnormal 12-lead ECG that may jeopardize the subject's ability to complete the study
Subject using any prescription drug for which concomitant beta-agonist administration is contraindicated